跳至主要内容
临床试验/NL-OMON55716
NL-OMON55716已完成不适用

Prospective, controlled, single-arm clinical investigation for the treatment of subjects with severe symptomatic aortic valve stenosis using Valvosoft® Pulsed Cavitational Ultrasound Therapy (PCUT) - First-In-Man. - VALVOSOFT® FIM-STUDY

CARDIAWAVE SA.0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Subjects suffering from severe symptomatic aortic valve stenosis according
  • to ESC 2017 definition, including subjects with a bicuspid valve.
  • 2. Patient is not eligible for TAVR/SAVR according to local Heart Team.
  • 3. Age >=18 years.
  • 4. Subjects who are willing to provide a written informed consent prior to
  • participating in this clinical investigation.
  • 5. Subjects who can comply with the study follow-up or other study requirements.
  • 6. Patient is eligible for the Valvosoft procedure according to CRC.

排除标准

  • 1. Subjects with any electrical device implanted.
  • 2. Subjects with unstable arrhythmia not controlled by medical treatment.
  • 3. Subjects with implanted mechanical valve in any position or bio prosthetic
  • valve in aortic position.
  • 4. Subjects with complex congenital heart disease.
  • 5. Chest deformity.
  • 6. Cardiogenic shock.
  • 7. History of heart transplant.
  • 8. Subjects requiring other cardiac surgery procedures (bypass graft surgery,
  • mitral valve procedure, tricuspid valve procedure) within one month after
  • 9. Thrombus in heart.
  • 10. Acute myocardial infarction, stroke or transient ischemic attack (TIA)
  • within one month prior to enrolment*.
  • 11. Subjects who are pregnant or nursing.
  • 12. Subjects who are participating in another research study for which the
  • primary endpoint has not been reached.

研究者

相似试验

Prospective, controlled, single-arm clinical... | 临床试验